ArticleFrontiers in oncology2023

Corrigendum: Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132.

Yezhe Cheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.